The nerve to expect more. The nerve to redefine patient expectations.
The VNS Therapy® System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications
Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom1
Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures2
Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years3,4
VNS Therapy™ can reduce the impact of seizures and can help improve post-ictal recovery
Clinically meaningful improvement from baseline8
VNS Therapy™ Can Provide Improvements in Seizure Control*
VNS Therapy™ Can De-Intensify and Seizures and Provide Improvements in Seizure Control*
mean follow-up 13 months (N=51)
59% reported ≥ 50% reduction in seizures
41% reported ≥ 80% reduction in seizures
*Data is from devices with AutoStim Mode enabled, which is only available in models 106, 1000, and 1000-D.
VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years
Mean reduction in seizure frequency7
3 out of 4 patients experienced improvements in overall QoL8
Cognitive and psychosocial benefits include improvements in†:
- Verbal skills
- Mood changes
†N=1194, maximum achieved follow-up range of 24–48 months.
VNS Therapy™ can reduce mood-related symptoms in patients with DRE
84% of patients experienced a reduction of depressive symptoms*1
*In a prospective study, K-BDI scores decreased by 32% between baseline and follow-up
Change in MADRS score: 38% reduction after VNS Therapy
Change in BDI score: 42% reduction after VNS Therapy
*VNS Therapy is not indicated to treat depression in drug-resistant epilepsy patients.
VNS Therapy™ has demonstrated safety and is well tolerated
The most common side effects occur during stimulation and typically become less noticeable over time.11,12 The most common side effect of the surgical procedure is infection.13
References: 1. Thurman DJ, Logroscino G, Beghi E, et al. Epilepsia. 2017;58(1):17-26. 2. Mula M, Zaccara G, Galimberti CA, et al. Epilepsia. 2019;60:1114-1123. 3. Alsfouk BAAA, Brodie MJ, Walters M, et al. JAMA Neurol. 2020;77(5):574-581. 4. Chen Z, Brodie MJ, Liew D, et al. JAMA Neurol. 2018;75(3):279-286. 5. Data on file, LivaNova, Inc., Houston, TX. 6. Datta P, Galla KM, Sajja K, et al. Epilepsy Behav. 2020;111:107280. doi: 10.1016/j.yebeh.2020.107280. 7. Elliot RE, Morsi A, Tanweer O, et al. Epilepsy Behav. 2011;20(3):478-483. 8. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 9. Spindler P, Bohlmann K, Straub HB, et al. Seizure. 2019;69:77-79. 10. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 11. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415-418. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX.